Joe Birkett

601 total citations
16 papers, 470 citations indexed

About

Joe Birkett is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Joe Birkett has authored 16 papers receiving a total of 470 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pathology and Forensic Medicine, 6 papers in Genetics and 5 papers in Oncology. Recurrent topics in Joe Birkett's work include Lymphoma Diagnosis and Treatment (7 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Joe Birkett is often cited by papers focused on Lymphoma Diagnosis and Treatment (7 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Joe Birkett collaborates with scholars based in United Kingdom, France and United States. Joe Birkett's co-authors include Guillaume Cartron, Gilles Salles, Franck Morschhauser, Thierry Lamy, Catherine Thiéblemont, Hervé Tilly, Nöel Milpied, V. R. Tindall, G. L. Foss and David Carlile and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The American Journal of Cardiology.

In The Last Decade

Joe Birkett

16 papers receiving 459 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joe Birkett United Kingdom 10 221 196 111 111 100 16 470
Stéphanie Bonnaud France 9 37 0.2× 30 0.2× 67 0.6× 82 0.7× 36 0.4× 12 524
Nicola J. Weston-Bell United Kingdom 10 36 0.2× 58 0.3× 27 0.2× 10 0.1× 53 0.5× 19 359
Arnaud Agin France 11 70 0.3× 22 0.1× 23 0.2× 48 0.4× 40 0.4× 25 542
E. J. Ebels Netherlands 14 75 0.3× 143 0.7× 48 0.4× 33 0.3× 15 0.1× 28 564
Stephanie Aungst United States 8 68 0.3× 25 0.1× 113 1.0× 28 0.3× 29 0.3× 8 698
S Stürzebecher United States 11 181 0.8× 9 0.0× 153 1.4× 20 0.2× 173 1.7× 18 587
Lucy Yan United States 5 121 0.5× 16 0.1× 49 0.4× 20 0.2× 15 0.1× 15 325
Shigeru Genka Japan 13 31 0.1× 154 0.8× 68 0.6× 19 0.2× 19 0.2× 20 529
Christoph Korenke Germany 14 120 0.5× 26 0.1× 20 0.2× 15 0.1× 18 0.2× 21 757
Jana Švarcová Czechia 12 81 0.4× 28 0.1× 31 0.3× 19 0.2× 31 0.3× 20 385

Countries citing papers authored by Joe Birkett

Since Specialization
Citations

This map shows the geographic impact of Joe Birkett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joe Birkett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joe Birkett more than expected).

Fields of papers citing papers by Joe Birkett

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joe Birkett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joe Birkett. The network helps show where Joe Birkett may publish in the future.

Co-authorship network of co-authors of Joe Birkett

This figure shows the co-authorship network connecting the top 25 collaborators of Joe Birkett. A scholar is included among the top collaborators of Joe Birkett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joe Birkett. Joe Birkett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
2.
Salles, Gilles, Franck Morschhauser, Thierry Lamy, et al.. (2012). Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood. 119(22). 5126–5132. 147 indexed citations
3.
Ogura, Michinori, Franck Morschhauser, Kensei Tobinai, et al.. (2010). Comparison of Single Agent GA101 In Japanese and European Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL) – Results From Two Phase I Studies. Blood. 116(21). 4921–4921. 1 indexed citations
4.
Meneses‐Lorente, Georgina, David Carlile, Joe Birkett, et al.. (2010). Pharmacokinetics of RO5072759 (GA101) In Patients with Relapsed/Refractory CD20+ Malignant Disease (Phase I/II Study BO20999). Blood. 116(21). 1833–1833. 6 indexed citations
5.
6.
Cartron, Guillaume, Catherine Thiéblemont, Philippe Solal‐Céligny, et al.. (2010). Promising Efficacy with the New Anti-CD20 Antibody GA101 In Heavily Pre-Treated NHL Patients – First Results From a Phase II Study In Patients with Relapsed/Refractory DLBCL and MCL. Blood. 116(21). 2878–2878. 13 indexed citations
7.
Morschhauser, Franck, Guillaume Cartron, Thierry Lamy, et al.. (2009). Phase I Study of RO5072759 (GA101) in Relapsed/Refractory Chronic Lymphocytic Leukemia.. Blood. 114(22). 884–884. 59 indexed citations
8.
Salles, Gilles, Franck Morschhauser, Guillaume Cartron, et al.. (2008). A Phase I/II Study of RO5072759 (GA101) in Patients with Relapsed/Refractory CD20+ Malignant Disease. Blood. 112(11). 234–234. 35 indexed citations
9.
Li, Tao, Clive Holmes, Pak C. Sham, et al.. (1997). Allelic functional variation of serotonin transporter expression is a susceptibility factor for late onset Alzheimerʼs disease. Neuroreport. 8(3). 683–686. 89 indexed citations
10.
Mehta, J, Larry M. Lopez, Prakash Deedwania, et al.. (1987). Similar efficacy of nitrendipine in young and elderly hypertensive patients. The American Journal of Cardiology. 60(13). 1096–1100. 6 indexed citations
11.
Krol, G.J., et al.. (1987). Disposition and Pharmacokinetics of 14C-Nitrendipine in Healthy Volunteers. Journal of Cardiovascular Pharmacology. 9. S122–S128. 21 indexed citations
12.
Krol, G.J., et al.. (1987). Bioequivalence of Different Nitrendipine Tablet Dosage Formulations. Journal of Cardiovascular Pharmacology. 9. S129–S135. 13 indexed citations
13.
Lettieri, John, G.J. Krol, S. S. C. YEN, et al.. (1987). Pharmacokinetics of Nitrendipine in Elderly and Young Healthy Volunteers. Journal of Cardiovascular Pharmacology. 9. S142–S147. 11 indexed citations
14.
Archambault, A, et al.. (1977). Evaluation of Duogastrome (carbenoxolone sodium) for the treatment of duodenal ulcer: a multicentre study.. PubMed. 117(10). 1155–9. 2 indexed citations
15.
Foss, G. L., V. R. Tindall, & Joe Birkett. (1973). THE TREATMENT OF SUBFERTILE MEN WITH CLOMIPHENE CITRATE. Reproduction. 32(1). 167–170. 43 indexed citations
16.
Foss, G. L., V. R. Tindall, & Joe Birkett. (1973). THE TREATMENT OF SUBFERTILE MEN WITH CLOMIPHENE CITRATE. Obstetrical & Gynecological Survey. 28(10). 756–757. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stéphanie Bonnaud Breakdown of academic impact, for papers by Nicola J. Weston-Bell Breakdown of academic impact, for papers by Arnaud Agin Breakdown of academic impact, for papers by E. J. Ebels Breakdown of academic impact, for papers by Stephanie Aungst Breakdown of academic impact, for papers by S Stürzebecher Breakdown of academic impact, for papers by Lucy Yan Breakdown of academic impact, for papers by Shigeru Genka Breakdown of academic impact, for papers by Christoph Korenke Breakdown of academic impact, for papers by Jana Švarcová
Rankless by CCL
2026